Notice type: 3rd Party Publications
Problem Or Issue:
Important Safety Information from Pfizer Healthcare Ireland regarding Xeljanz (tofacitinib): Increased risk of major adverse cardiovascular events and malignancies with use of tofacitinib relative to TNF-alpha inhibitors
Important Safety Information - Xeljanz (tofacitinib)